Many rheumatologists need to go through the recertification process. The ABIM handling of this "requirement" has generated heated discussions over what appears to be an expensive, onerous, and irrelevant effort.
The 4th annual IFPA meeting was held in Stockholm, Sweden on July 9-11, 2015. Leading experts discussed advances in research, therapy and patient care for psoriasis and psoriatic arthritis.
Wine and the rheumatologist in theory could be about a lot of things. Naturally, as rheumatologists, we are interested in how wine may affect rheumatic diseases. I am more inclined to write about how our community interacts around and enjoys wine.
In this edition of “Across the Table”, Drs. Cush and Schwartman discuss uveitis. Our expert, Dr. Sergio Schwartzman offers up his approach to diagnosis and management.
What is going on in the wide and wacky world of pain and fatigue? What use to be called fibromyalgia is being reclassified as myalgic encephalomyelitis (ME/CFS) or systemic exertion intolerance disease. Although fibromyalgia has many faces, it does not deserve many names.
Fatigue is not far behind pain as the complaint that affects the quality of life in numerous rheumatic and autoimmune disorders. But do we need to focus on fatigue in our disease management?
There are no detailed recommendations agreed upon by SLE experts on what treatment to use after first and second (and often third) line treatment has failed.
If you’re going to spend 10-20% of your clinic hours examining and caring for 28 or 68 or 360 joints – it may be instructive to own up to those joints we excel at and take note of the ones we avoid, despise or struggle with.
Adult-onset Still's posses a interestng and diagnostic challeng when encountered. Here are 5 tips to improve your diagnostic acumen for this febrile disorder.
The DRESS syndrome is a rare and sometimes catastrophic disorder resulting from specific drug exposures, including allopurinol, minocycline, INH, anticonvulsants or retroviral agents.
I was recently asked, “what is the best kind of arthritis to have?” My response is based on diagnosibility, treatability and safety of necessary treatment.
Drug efficacy is swiftly proven in phase II and III trials. Yet drug safety requires time, wider exposure, physician education and patient acceptance to be fully established.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
